Cat scratch disease (CSD), or ocular Bartonellosis, is a self-limited, systemic illness caused by a gram-negative bacillus, Bartonella henselea. It usually presents as a benign tender lymphadenitis involving the lymph nodes draining dermal or conjunctival sites of inoculation. Cat-scratch disease has been shown to be a worldwide zoonotic infection. 6 Cats are the primary mammalian reservoir for B. henselae7 and infection rates in cats appear to be higher in areas with more fleas. Primary inoculation often results in a systemic infection. The infected individual often develops an erythematous papule, vesicle, or macule at the site of inoculation followed by a systemic reaction within few weeks. The eye can be involved either with the primary inoculation complex, resulting in the so-called Parinaud oculoglandular syndrome or by haematogenous spread, leading to an array of ocular and neuroophthalmic complications. Parinaud oculoglandular syndrome appears to be the most common ocular complication of cat scratch disease, affecting approximately 5 percent of symptomatic patients. The regional lymphadenopathy involving the preauricular, submandibular, or cervical lymph nodes slowly resolves over several months. CSD is the most common identifiable cause of neuroretinitis. The condition is usually unilateral but may be bilateral. CSD may be suspected in patients with a regional lymphadenopathy with mild fever and malaise. The blood culture isolation of B. henselae is difficult and expensive. The diagnosis of CSD is now possible through 2 serologic tests currently available. An indirect fluorescent antibody (IFA) test was developed to detect the humoral response to the organism. The differential diagnosis for Parinaud’s oculoglandular syndrome includes tularemia, tuberculosis, syphilis, rickettsiosis, infectious mononucleosis, sporotrichosis, and acute Chlamydia trachomatis infection. Retinitis and chorioretinitis associated with CSD can be distinguished from other infectious or noninfectious entities on the basis of history, systemic signs and symptoms, and the pattern of ocular involvement. There are no clear recommendations for the treatment of CSD or its ocular complications. Immunocompetent patients with B. henselae infections generally resolve completely without treatment. Many physicians do not treat mild to moderate systemic CSD. They treat severe ocular or systemic complications of B. henselae infection in immunocompetent patients, and all immunocompromised patients.